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CO2 exposure as translational cross-species experimental
model for panic
NK Leibold1,2,3, DLA van den Hove1,2,4, W Viechtbauer1,2, GF Buchanan3,5, L Goossens1,2, I Lange1,2, I Knuts1,2, KP Lesch1,2,4,
HWM Steinbusch1,2 and KRJ Schruers1,2,6
The current diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders are being challenged by the
heterogeneity and the symptom overlap of psychiatric disorders. Therefore, a framework toward a more etiology-based
classiﬁcation has been initiated by the US National Institute of Mental Health, the research domain criteria project. The basic
neurobiology of human psychiatric disorders is often studied in rodent models. However, the differences in outcome
measurements hamper the translation of knowledge. Here, we aimed to present a translational panic model by using the same
stimulus and by quantitatively comparing the same outcome measurements in rodents, healthy human subjects and panic disorder
patients within one large project. We measured the behavioral–emotional and bodily response to CO2 exposure in all three
samples, allowing for a reliable cross-species comparison. We show that CO2 exposure causes a robust fear response in terms of
behavior in mice and panic symptom ratings in healthy volunteers and panic disorder patients. To improve comparability, we next
assessed the respiratory and cardiovascular response to CO2, demonstrating corresponding respiratory and cardiovascular effects
across both species. This project bridges the gap between basic and human research to improve the translation of knowledge
between these disciplines. This will allow signiﬁcant progress in unraveling the etiological basis of panic disorder and will be highly
beneﬁcial for reﬁning the diagnostic categories as well as treatment strategies.
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INTRODUCTION
Currently, the diagnoses of psychiatric disorders are based on the
Diagnostic and Statistical Manual of Mental Disorders (DSM),1
which speciﬁes the minimum number and duration of symptoms
that must be present for a particular diagnosis. The symptom-
based categories of DSM have been the gold standard for many
years; however, the heterogeneity and symptom overlap of many
mental disorders challenge this categorical approach. Therefore, a
new framework toward a novel dimensional classiﬁcation based
on integrating behavior and neurobiological measures has been
initiated by the US National Institute of Mental Health, the
research domain criteria.2 It is expected that combining self-
reports with assessment of behavior, genetics and neural circuitry
will lead to a more etiology-based diagnosis rather than a mainly
symptom-driven one, ultimately leading to improved treatments
in the long term.
Although behavioral and genetic assessments are technically
feasible in humans, the potential to study neural circuitries is
limited. Therefore, a vast proportion of research into the basic
neurobiology of human psychiatric conditions is carried out in
other species, making use of animal (mainly rodent) models of
psychopathology. A major challenge in this respect is the
translation of data from research in animals to humans and,
ultimately, patients with a psychiatric disorder. To maximize the
efﬁcacy of translation, the rodent model should resemble the
aspects of the disorder in humans as much as possible.
To judge the degree of an animal model reﬂecting the disorder
of interest, the following criteria are commonly used:3 (1) face
validity, indicating the resemblance between the behavior in the
model and the symptoms of the disorder, (2) predictive validity,
referring to the degree the impact on the model predicts the
outcome in the disorder and (3) construct validity, referring to the
degree of similarity between the etiological mechanisms under-
lying behavior in the rodent model and in the disorder. In the past
few years, important progress has been made in psychiatry
research using well-validated animal models. For instance, the
assessment of prepulse inhibition, a measure of sensorimotor
gating, in rodents, has led to insight in sensory processing in
humans and has contributed to the knowledge of the neuronal
dysfunctions in psychiatric disorders such as schizophrenia.4 Such
an example is rare in psychiatry, however.
Panic attacks (PAs) are a common psychopathological phenom-
enon throughout many psychiatric disorders, but most notably
they are the core feature of panic disorder (PD).1 It has been well
established that PAs can be reliably provoked in the laboratory
using a brief inhalation of 35% CO2.
5–11 Originally, it was believed
that the hyper-reactivity to such a CO2 inhalation was speciﬁc to
PD.12–15 However, a recent series of studies showed that PAs can
also be reliably induced in healthy subjects, depending on the
concentration of CO2 and personal sensitivity.
6,16 The ﬁnding that
panic can thus be studied in healthy volunteers is important as
major confounders that are present in patient populations, such as
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comorbidity or the use of medication, can be avoided. In addition,
the observation that patients are more sensitive to CO2 than
healthy individuals demonstrates the existence of a continuous
CO2 sensitivity spectrum based on common fundamental
mechanisms that are present in every individual. Human studies
showed that PD has a heritability of ~ 40%17 and that the
individual differences in the sensitivity to CO2 can be, in part,
attributed to genetic factors.18–20 A higher concordance was
found for monozygotic twins compared with dizygotic ones,21 and
healthy ﬁrst-degree relatives of PD patients have an elevated
sensitivity to CO2, which is intermediate between healthy
individuals without a familial history of PD and PD patients.22–24
In recent rodent studies, inspired by the use of CO2 as human
experimental model for panic, animals were exposed to concen-
trations of up to 20% CO2 in order to investigate the basic
mechanisms of fear.25–29 Quantitative genetic research in rodent
unrelated individuals, sibs and half-sibs support a genetic
contribution in the sensitivity to CO2.
29 Other seminal discoveries
were made such as the essential role of pH-sensitive ion
channels27 and that of orexin26 in CO2-induced rodent fear
behavior. The use of experiments that represent the human
models as closely as possibly27,29,30 is an important element in the
application of these basic ﬁndings to the study of fear in humans.
However, translation is commonly hampered by the fact that
rodent and human studies use very different outcome measures.
Most human panic studies rely on self-reports of fear and
discomfort levels, whereas animal studies primarily use behavioral
assays to assess the fear and distress evoked by CO2 in
relationship to neurobiological alterations. Additional outcome
measures in both species might allow a better comparison of
the data.
In the present paper, we present data from three translational
studies applying CO2-induced fear in rodents, healthy human
individuals and PD patients. Apart from the traditional outcome
measures (behavioral tests in mice and symptom reports in
humans), we present data from comparable physiological
measurements in both species. We thus aim to present a
translational experimental panic model combining three samples
within one project.
MATERIALS AND METHODS
Study 1: mice
Animals. In total, 20 male wild-type C57BL/6 mice were housed within a
temperature-controlled environment and under a reversed day/night cycle
(12 h dark/12 h light cycle). Animals had access to standard rodent chow
and water ad libitum. For behavioral testing, mice were assigned to either
CO2 exposure (n= 10) or air exposure (n= 10). The physiological response
to both room air and CO2 exposure was tested in the same animals
(n= 20). Sample sizes were calculated using G*Power 3.1.9.2 (ref. 31) and
the parameters alpha= 0.05 and power = 0.8. For the between-subject
comparison, the calculation was based on independent t-test (two-tailed,
d= 1.4 based on previous behavioral experiments) and the within-subject
comparison on two dependent means (two-tailed, d=0.7 based on
previous experiments). Animals were assigned to groups in a semi-
randomized manner by an investigator not directly involved in the testing
and ensuring a balanced age distribution among groups. Testing was
performed from a mean age of 58 days onward under low-light conditions
by an investigator aware of experimental condition to ensure exposure to
the right CO2 concentration. Using a computer program the order of
testing animals was randomized and kept for all experiments. Behavioral
analysis of video ﬁles was performed by an investigator blinded to the
experimental conditions. All procedures and experiments were approved
by the Institutional Animal Care and Use Committee at Yale University,
New Haven, CT, USA. Animals were handled in accordance with the
institutional guidelines.
CO2 exposure and behavioral testing
Open ﬁeld test: For the ﬁrst behavioral test, the open ﬁeld test (OFT), a
transparent Plexiglas square chamber (60 × 60 × 40 cm), covered with a
clear lid, was used. The ﬂoor was subdivided into a 30 × 30 cm central zone,
15 × 15 cm corners and 30 × 15 cm walls. Depending on the experimental
group, the chamber was pre-ﬁlled with 9% CO2 (normoxic mixture;
compressed air tanks, Airgas East, Cheshire, CT, USA) or air. Gas infusion
ports and two CPU fans (21 dB, ebm-papst, St Georgen, Hungary) to ensure
a homogenous concentration of CO2 throughout the chamber were
located on the upper part of the box to avoid blowing, which may be
aversive to mice. The concentration of CO2 was constantly controlled using
a digital CO2 meter (30% CO2 Sampling Data Logger, CO2 meter, Ormond
Beach, FL, USA). After pre-ﬁlling the chamber with gas, mice were placed in
the center of the chamber and were allowed to explore the chamber for
20 min.27 Movements were recorded automatically with a computerized
system (Ethovision Pro, Noldus, Wageningen, the Netherlands). The
number of fecal pellets was scored at the end of each trial by the
experimenter. The box was cleaned with 70% ethanol between trials to
avoid olfactory cues.
Two-chamber test: Three days after the OFT, animals were tested in
the two-chamber test (TCT). The testing apparatus consisted of two
chambers (each 30× 30 cm with 40 cm high walls), which were connected
by an open door (3.5 × 3.5 cm) to allow free crossing. Each chamber had
a gas infusion port and a CPU fan (21 dB, ebm-papst) to ensure a
homogenous gas concentration throughout the entire part. For mice
subjected to CO2 exposure, one chamber was pre-ﬁlled with CO2 and the
other one with room air. Gas concentrations were controlled continuously
using a digital CO2 meter (30% CO2 Sampling Data Logger, CO2 meter;
reaching a steady state of 9% and 2% CO2, respectively). For mice assigned
to air exposure, air was used in both chambers. Side of CO2 administration
and side in which the mouse was placed were randomized using a
computer program. Movements were recorded automatically with a
computerized system (Ethovision Pro, Noldus) for a period of 10 min. The
number of fecal pellets was scored at the end of each trial by the
experimenter. Ethanol (70%) was used to clean the chambers between
trials to avoid olfactory cues.
CO2-evoked freezing: Freezing was scored in both behavioral tests by
a trained observer and was deﬁned as absence of any movements apart
from respiration.
Breathing and cardiovascular recordings. After completion of the beha-
vioral tests, breathing and the cardiovascular response were assessed in all
animals. Mice were placed into a custom-made whole-body recording
chamber (Plexiglas, 350 cm3). Animals were habituated to the chamber for
30 min (with room air infusion). Then, the physiological response was
measured in a ﬁxed order: room air exposure for 20 min and subsequently
9% CO2 for 10 min. Flow rates (0.4 l min
− 1) were controlled with a digital
ﬂowmeter (WU-32446-33, Cole-Parmer, Hoffman Estates, IL, USA).
Breathing and cardiovascular recordings were obtained non-invasively
and simultaneously. Breathing was assessed using a low-volume pressure
transducer (DC002NDR5; Honeywell International, Minneapolis, MN, USA)
that was ﬁtted to the recording chamber. Breathing-induced pressure
changes were calibrated with 150 pulses per min, each 300 µl. Relative
humidity (HIH-4602-A sensor; Honeywell International, Minneapolis, MN,
USA) and ambient temperature (BAT-12 microprobe, Physiotemp Instru-
ments, Clifton, NJ, USA) were measured continuously within the recording
chamber. Electrodes for electrocardiogram measurements were placed on
both sides of the shaved thorax and connected to an ampliﬁer (Model 440
Instrumentation Ampliﬁer, Brownlee Precision, San Jose, CA, USA). Blood
pressure was not assessed as common methods such as the use of a tail
cuff do not allow monitoring in freely moving animals or require prior
surgery as it is the case in telemetry. Animal temperature was measured
rectally immediately after completion of the recording (BAT-12 microp-
robe, Physiotemp Instruments). All signals were digitized with an analog-
to-digital converter (PCI-6221 or USB-6008 National Instruments, Austin,
TX, USA) and were displayed in a custom-written acquisition program in
Matlab (version R2011b, Mathworks, Natick, MA, USA).
Study 2: healthy volunteers
Participants. In total, 136 adult healthy volunteers (mean age 22.81 years,
s.d. = 8.89, 44 males) were recruited via advertisements at Maastricht
University, the Netherlands (part of a previous sample32 extended with
new participants (n= 79)). The subsamples did not differ signiﬁcantly
regarding demographics (age and sex), psychometric scales (fear and panic
scores) or physiology (independent samples t-test). As the smallest effects
were expected for 0% CO2 compared with 9% CO2 (see ‘CO2 inhalation and
fear/panic scores’ for details about the used concentrations), the sample
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size calculation was based on this comparison using a dependent means
test in G*Power 3.1.9.2 (ref. 32) (two-tailed, alpha= 0.05, power = 0.8,
d= 0.25 based on a previous pilot study assessing the cardiovascular
effects to CO2, leading to a total sample size of 128). Before participating,
eligibility was conﬁrmed using a medical examination and a
semi-structured psychiatric interview (including the Mini International
Neuropsychiatric interview33). Pre-deﬁned exclusion criteria were current
or past cardiovascular or pulmonary disease, hypertension (systolic/
diastolic 4170/100 mmHg), familial or personal history of cerebral
aneurysm, excessive smoking (415 cigarettes per day), pregnancy,
epilepsy, use of psychotropic medication or adrenergic receptor blockers
and a ﬁrst-degree relative with PD. All participants gave written informed
consent before the study, which was approved by the Medical Ethics
Committee of Maastricht University and the Maastricht University Hospital.
CO2 inhalation and fear/panic symptom scores. After conﬁrming eligibility,
participants took a double vital capacity breath of four CO2 concentrations
according to a double-blind, randomized, cross-over design: 0, 9, 17.5 and
35% CO2 (normoxic gas mixture; premixed gas tanks obtained from
Nederlandse Technische Gasmaatschappij, Landgraaf, the Netherlands).
A computer program determined a random order for each individual,
which was veriﬁed by an independent investigator to ensure that each
concentration was applied once. The double vital capacity breath of 35%
CO2 induces a condition complying with the formal criteria of panic in the
current psychiatric nosology.16 Each inhalation was performed according
to a standardized protocol in our laboratory.6,16,32 More speciﬁcally, after
being seated in an armchair, a nasal–oral mask was ﬁxed to the
participant’s head. The vital capacity of a double breath was measured
using a digital ﬂowmeter. All participants were told that the subsequent
CO2 inhalation might cause some effects, ranging from vague sensations
up to fear. However, all effects would be short-lasting. Subsequently,
participants took a double vital capacity breath of one CO2 mixture.
Participants were motivated to inhale at least 80% of the vital capacity.
Inhalations took place on four separate days, each day at the same time for
each participant. Participants were instructed to refrain from caffeine-
containing beverages on the inhalation days.
Presence and intensity of fear and panic symptoms were obtained twice:
immediately before the inhalation, patients were asked to rate their
sensations at that particular moment and after the inhalation to rate the
sensations at the worst moment of the inhalation. Feelings of fear were
evaluated using the Visual Analog Scale for fear (VAS-F), a horizontal line of
100 mm length that ranges from 0 (not at all) to 100 (the worst
imaginable). Panic symptoms were assessed using the Panic Symptom List
(PSL), consisting of the 13 DSM PA symptoms and ranging from 0 (absent)
to 4 (very intense).
Breathing and cardiovascular recordings. Physiological parameters were
measured throughout all four CO2 inhalation using a computerized system
(Carbon Dioxide Tolerance Tester, Maastricht Instruments, Maastricht, the
Netherlands) as previously described.32 A soft plastic nasal–oral mask was
ﬁxed to the participant’s head and was connected to a capnograph device
(Medair, Delsbo, Sweden) to measure the respiration rate. A ﬁnger cuff,
connected to a cardiovascular monitor (Nexﬁn, Bmeye, Amsterdam, the
Netherlands), was ﬁxed to the middle ﬁnger of the non-dominant hand to
assess heart rate and blood pressure (sampling rate 2 Hz). All measure-
ments were acquired with a custom-made software (IDEEQ, Maastricht
Instruments).
Study 3: PD patients
Participants. Ninety-eight adult patients with PD (mean age 35.21 years,
s.d. = 11.65, 63 males) from the outpatient setting of the Academic Anxiety
Centre, Maastricht, the Netherlands, voluntarily participated in this study.
To compare the CO2-induced effects in PD patients with healthy
individuals, a test for independent means was used in G*Power 3.1.9.2
(ref. 32) (two-tailed, alpha= 0.05, power = 0.8, d=0.4 based on a previous
pilot study). PD (with or without agoraphobia) as the main diagnosis was
established via a semistructured psychiatric interview (including the Mini
International Neuropsychiatric interview33) by an experienced psychiatrist.
In addition, a medical examination took place. Pre-deﬁned exclusion
criteria were current or past cardiovascular or pulmonary disease,
hypertension (systolic/diastolic 4170/100 mmHg), familial or personal
history of cerebral aneurysm, pregnancy and epilepsy. All participants
provided written informed consent. The study was approved by the
Medical Ethics Committee of Maastricht University and the Maastricht
University Hospital.
CO2 inhalation and fear/panic symptom scores. Patients took a single vital
capacity breath of 35% CO2 (premixed gas tanks obtained from
Nederlandse Technische Gasmaatschappij) according to a repeatedly
used and standardized protocol in our laboratory.11,34 We previously
showed that this inhalation provokes the fear and panic symptoms in
patients resembling a real-life PA,11 whereas in healthy individuals a
double breath induces qualitatively comparable effects.16 Patients were
seated in an armchair and instructed into the use of a self-administering
nasal–oral mask. The vital capacity of a single breath was measured using a
digital ﬂowmeter. Then, the patients were informed that the subsequent
CO2 inhalation might cause some effects, ranging from vague sensations
up to fear. However, all effects would be short-lasting. Patients took a
single vital capacity breath of 35% CO2 and were motivated to inhale
at least 80% of the previously measured vital capacity. Patients were
instructed to refrain from caffeine-containing beverages on the
inhalation day.
Likewise to the assessment in healthy volunteers, fear and panic
symptom scores were obtained immediately before and after the CO2
inhalation. The VAS-F was used to assess fear (ranging from 0, not at all, to
100, the worst imaginable) and the PSL for assessing the 13 symptoms of a
PA (ranging from 0, absent, to 4, very intense).
Breathing and cardiovascular recordings. As in healthy individuals,
physiological recordings were obtained using a computerized system
(Carbon Dioxide Tolerance Tester, Maastricht Instruments) throughout the
entire procedure. Measuring the respiration rate implies using a mask ﬁxed
to the head, which was not tolerated by the patients in a pilot study in our
laboratory. Therefore, we only recorded heart rate and blood pressure,
which we measured using a ﬁnger cuff that was ﬁxed to the middle ﬁnger
of the non-dominant hand (sampling rate 2 Hz). The ﬁnger cuff was
connected to a cardiovascular monitor (Nexﬁn, Bmeye). All measurements
were collected and displayed in the custom-made software (IDEEQ,
Maastricht Instruments).
Data and statistical analysis
For all analyses, statistical signiﬁcance was set at Po0.05 (two-tailed).
Assumptions for tests such as normal distribution, homoscedasticity and
(in)dependence of observations were checked and met. Analyses were
carried out using the software R (version 3.1.1, 2014, R Development Core
Team, Vienna/Austria) or the Statistical Package for the Social Sciences
(SPSS 20.0.0.1 for Mac; SPSS, Chicago, IL, USA). Values are presented as
means+s.e.m.
Animal behavioral data. Rodent behavior was analyzed using univariate
analysis of variance or independent t-tests for unequal variances, when
appropriate. Regarding the TCT, within a group, repeated measures
analysis was applied. To take freezing behavior into account, the ratio for
freezing in a particular chamber divided by the time spent in that chamber
was calculated.
Human symptom reports. In humans, self-reports were analyzed in terms
of change in fear and panic symptoms as calculated by subtracting the
rating before the CO2 inhalation from the post rating. In healthy
volunteers, multilevel models with an unstructured variance–covariance
matrix were used to account for the fact that the subjects underwent four
CO2 concentrations. A signiﬁcant overall test effect was examined in more
detail by testing pairwise comparisons using Holm’s method to control for
the family-wise error rate.35 Patients and healthy volunteers were
compared using univariate analysis.
Physiological measurements: animals and humans. In rodents, ~ 400
breathing-induced pressure oscillations were analyzed of the second half
of each gas exposure phase. Moving artifacts, coughing, sighs and snifﬁng
were excluded. Interbreath interval, tidal volume and ventilation were
calculated for all mice. The animal temperature obtained immediately after
the recording was used to calculate tidal volume and ventilation, which
were corrected to animal weight in grams. With regard to electrocardio-
gram data, 30 s were analyzed of the second half of each gas exposure
phase. Electrocardiogram data were further analyzed using the quick peaks
gadget in Origin 9.0 (OriginLab, Northampton, MA, USA).
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In humans, physiological data were averaged to the means per second.
The 10 s before the inhalation were taken as baseline and 30 s after
inhaling CO2 (starting after breath holding for 4 s) to assess the effects of
the exposure. This period was chosen based on the observation that most
individuals reach a symptomatic peak within the ﬁrst 10–15 s, after which
the symptoms quickly disappear. Owing to technical failure, the ﬁnal
sample varied per outcome and CO2 concentration: healthy volunteers—
cardiovascular parameters n= 117–136, respiratory outcomes n= 47–62;
PD patients—cardiovascular parameters n= 98 (see Supplementary Table 2
for exact sample sizes).
To be able to compare the effects between mice and humans, effect
sizes were calculated for physiological parameters by subtracting the mean
value during air exposure from the mean value of the CO2 exposure, which
was then divided by the s.d. of the air exposure. Effect sizes were
statistically compared between conditions using z-tests, corrected for
multiple testing.
RESULTS
Behavioral response to CO2 exposure in mice
In the OFT, mice exposed to 9% CO2 for 20 min covered
signiﬁcantly less distance (F(1, 18) = 274.854, Po0.001,
Figure 1a), spent less time in the center zone (F(1, 18) = 10.610,
P= 0.004, Figure 1b) and spent more time in the corner zones in
comparison with air-exposed mice (F(1, 18) = 43.073, Po0.001,
see Supplementary Table 1). Mice also showed a marked freezing
response, considered to be a reﬂection of fear-related behavior in
rodents,36 when exposed to CO2 compared with exposure to air
(t(9.031) =− 6.164, Po0.001, Figure 1c). Next, we used a 10 min
TCT, with one chamber ﬁlled with CO2 and one with air, or both
chambers ﬁlled with air. Overall, CO2 exposure decreased the
distance moved when compared with air exposure only (F(1,
17) = 35.826, Po0.001, Figure 1d). In addition, the total number of
crossings between the two chambers was signiﬁcantly lower in
the group exposed to CO2 (F(1, 17) = 8.080, P = 0.011, see
Supplementary Table 1). Time spent did not differ between the
chamber ﬁlled with CO2 and the one ﬁlled with air (F(1) = 0.020,
P= 0.891, see Supplementary Table 1). However, mice showed a
marked freezing response when exposed to CO2 in one chamber
compared with mice exposed to air only (t(8.005) =− 3.656,
P= 0.006, Figure 1e). This response was particularly robust in the
chamber ﬁlled with CO2 compared with the air chamber (F
(1) = 9.009, P= 0.017, see Supplementary Table 1). As the freezing
duration inﬂuences the time spent in the chambers, the ratio of
freezing and time spent in a particular chamber was calculated,
conﬁrming that the freezing response was most pronounced in
the CO2 chamber, although this did not reach statistical
signiﬁcance (F(1) = 3.757, P= 0.110, Figure 1f). Further, on average,
the number of fecal pellets, a relative measure of anxiety/fear in
rodents,37 signiﬁcantly increased under CO2 exposure (F(1, 18) =
12.211, P = 0.003, see Supplementary Table 1).
Figure 1. Effect of CO2 exposure on behavior in mice. In the open ﬁeld test (OFT), CO2 exposure decreased the total distance moved (a) and
the time spent in the center zone (b). (c) Under CO2 exposure mice froze signiﬁcantly more than under air exposure. (d) In the two-chamber
test (TCT), mice exposed to CO2 in one chamber covered less distance than mice exposed to air only. (e) CO2-exposed mice froze signiﬁcantly
more than animals exposed to air. (f) Correcting for the time spent in each chamber conﬁrmed that freezing was strongest in the CO2
chamber, which however did not reach statistical signiﬁcance. Data represent mean+s.e.m. **Po0.01, ***Po0.001.
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Symptom reports to CO2 exposure in healthy individuals and PD
patients
In humans, we ﬁrst measured the behavioral response to CO2 by
means of a VAS-F and the PSL. In healthy individuals, taking a
double vital capacity breath of four different CO2 concentrations
up to 35% CO2,
6,16 VAS-F and PSL ratings increased dose-
dependently (VAS: F(1) = 227.866, Po0.001, PSL: F(1) = 275.359).
PD patients, taking a single vital capacity breath of 35% CO2,
8,11
also reported a strong fear and panic symptom response to CO2
(VAS: F(1) = 19.078, Po0.001, PSL: F(1) = 275.359, Po0.001;
Figures 2a and b).
Physiological response to CO2 exposure in mice, healthy
volunteers and PD patients
In a next conceptual step, toward a more objective quantitative
comparison, we measured the physiological response to CO2
exposure (see Supplementary Table 2 for means ± s.e.m.). In mice,
exposure to 9% CO2 caused a robust increase in the respiration
rate (Figure 3a, see Supplementary Table 3 for additional
respiratory measurements). In healthy volunteers, no difference
was found between 0 and 9% CO2 (z= 1.1, P= 0.270), and both
caused a lower mean respiration rate compared with baseline
(Figure 3a). At CO2 concentrations of 9% and higher there was a
relative increase in effect size (9% compared with 17.5%:
z=− 3.61, Po0.001; 17.5% compared with 35%: z=− 5.5,
Po0.001). Only 35% CO2 caused an increase in the mean
respiration rate compared with baseline, yielding a positive effect
size. The increase in the respiration rate was more pronounced in
mice after prolonged exposure to 9% than in healthy volunteers
after taking a double breath of 35% CO2 (z= 3.055, P= 0.002).
Regarding the heart rate, a CO2-induced decrease was observed
across species, with a particularly strong effect in mice (compared
with healthy individuals 35% CO2: z=− 2.599, P = 0.009; compared
with PD patients 35% CO2: z =− 3.160, P= 0.002; Figure 3b).
Further, in healthy volunteers, after inhaling 0 and 9% CO2, the
mean blood pressure decreased, whereas an increase was
observed after inhaling an intermediate (17.5%) and high (35%)
concentration of CO2. Pairwise comparisons revealed signiﬁcant
differences between all CO2 concentrations regarding the systolic
(0% compared with 9%: z=− 6.78, Po0.001; 0% compared with
17.5%: z=− 12.20, Po0.001; 0% compared with 35%: z=− 13.84,
Po0.001; 9% compared with 17.5%: z=− 8.23, Po0.001; 9%
compared with 35%: z=− 10.46, Po0.001; 17.5% compared with
35%: z=− 3.01, P= 0.003; Figure 3c) and the diastolic blood
pressure (0% compared with 9%: z=− 6.71, Po0.001; 0%
compared with 17.5%: z=− 12.21, Po0.001; 0% compared with
35%: z=− 15.63, Po0.001; 9% compared with 17.5%: z=− 8.31,
Po0.001; 9% compared with 35%: z=− 12.87, Po0.001; 17.5%
compared with 35%: z=− 6.67, Po0.001; Figure 3d). On average,
the effect size with regard to the systolic blood pressure tended to
be higher in PD patients in comparison with healthy volunteers
(z= 1.83, P= 0.067), whereas the effect size of the diastolic blood
pressure was lower in patients than in healthy volunteers (z= 3.89,
Po0.001).
DISCUSSION
The incongruence between rodent and human experimental fear
models hampers the translation of ﬁndings obtained in the two
species. The present study bridges this gap by applying the same
stimulus, that is, CO2, and obtaining a quantitative comparison of
the same physiological outcome parameters in addition to
commonly used behavioral phenotypes in three samples: in mice,
healthy volunteers and PD patients. Using this approach, we
showed that in both human samples CO2 triggers a marked fear
response associated with an increase in blood pressure, an
adaptive decrease in the heart rate and in healthy individuals an
increase in respiration rate. A comparable behavioral and
physiological response was observed in mice, demonstrating
corresponding effects across species.
The use of a CO2 inhalation in form of a single vital capacity
breath of 35% CO2 as human experimental model for panic was
ﬁrst established in PD patients.38 In contrast to initial
assumptions,12–15 the reactivity to CO2 is not limited to PD
patients. Meanwhile, it has been repeatedly shown that CO2
induces a dose-dependent state of experiencing fear and panic
symptoms in healthy individuals.7,39 This observation implies that
the reactivity to CO2 is a continuously distributed trait and
suggests the existence of a sensitivity spectrum, with PD patients
being at the highest end of sensitivity. This notion is supported by
imaging studies.40–42 Here we provide, for we believe the ﬁrst
time, a direct quantitative comparison of the response to CO2
between PD patients and healthy individuals. It has been well
established that inhaling CO2 triggers the emotional response and
panic symptoms in PD patients associated with real-life PAs5,11 as
well as in healthy individuals complying with the formal criteria of
a PA in the current DSM, when using a higher concentration.16
Figure 2. Effect of CO2 on self-reported fear and panic symptoms in healthy volunteers and PD patients. In healthy volunteers (gray), both fear
(a) and panic symptoms (b) increased dose-dependently. Inhaling 35% CO2 triggered a more robust response in patients (black) when
compared with healthy volunteers. Data represent mean+s.e.m. (a) Compared with 0% CO2, Po0.001; (b) compared with 9% CO2, Po0.001;
(c) compared with 17.5% CO2, Po0.001; **Po0.01. PD, panic disorder; PSL, Panic Symptom List; VAS-F, Visual Analog Scale for fear.
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However, that comparison in healthy individuals was qualitative in
nature. The quantitative comparison of the physiological response
in the present study shows that several physiological outcome
measurements of healthy individuals were statistically comparable
to those of PD patients. This suggests that the physiological
reactivity induced by a double vital capacity breath of 35% CO2 in
healthy individuals reﬂects well the reactivity provoked by a single
vital capacity breath of 35% CO2 in PD patients, thus further
supporting the potential to study healthy individuals before
involving patients to avoid confounding effects from comorbid
psychiatric disorders or current/past treatments. However, it has to
be taken into consideration that, whereas the reactivity is similar
on the physiological level, PD patients have a stronger emotional
response to CO2 than healthy individuals.
To explore the underlying basic mechanisms of panic, CO2
exposure has also been applied in rodents.25–28 The assessment of
the behavioral response requires a long exposure to CO2, which
makes it unfeasible to apply the high dosage of 35% that is used
in humans. The lower concentrations of CO2 in the healthy
individuals thus serve to make the bridge to the lower CO2
concentrations in the animal study. Up to now it was unclear to
what extent CO2 exposure in rodents represents a good
experimental model for panic in humans. In order to determine
this, the model can be judged on the criteria of face, predictive
and construct validity.3 Increasing evidence, including the present
study, supports a relatively good face validity.
CO2 exposure provokes a robust behavioral fear response in
humans and in rodents. In humans, this response is expressed in
terms of self-reported fear and panic symptoms in the present and
other studies,11,16 whereas in rodents it is expressed in terms of
the behavioral response itself, particularly freezing is considered to
reﬂect fear-related behavior.36 In the present study, we observed
that, for example, the distance moved was strongly reduced in
both the OFT and the TCT when animals were exposed to CO2
compared with air exposure. Thereby, our data conﬁrm previous
studies regarding the CO2-induced behavioral effects in
rodents.25–27 However, in the TCT, in contrast to a previous
report27 and our expectation, mice did not spend less time in the
chamber ﬁlled with CO2 than in the chamber ﬁlled with air. When
inhaling CO2 or during a PA, humans often attempt to avoid the
aversive situation. Analogously, we expected mice to avoid the
aversive effects of CO2. This was, however, not the case. This
ﬁnding might be explained by the very strong observed freezing
response that prevented the animals from leaving the chamber
Figure 3. Effect of CO2 on respiration rate, heart rate and blood pressure in mice, healthy volunteers and panic disorder (PD) patients. (a) In
mice (dashed), CO2 strongly increased the respiration rate compared to baseline (yielding a positive effect size), which was also observed in
healthy volunteers (gray) after inhaling 35% CO2. (b) CO2 exposure decreased the heart rate in all groups, particularly in mice. (c, d) in healthy
volunteers, 17.5 and 35% CO2 increased the blood pressure compared to baseline, which was also the case for PD patients (black) after 35%
CO2. Data represent effect sizes+s.d. (a) Compared with 0% CO2, Po0.05; (b) compared with 9% CO2, Po0.05; (c) compared with 17.5% CO2,
Po0.05; ***Po0.001; **Po0.01.
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ﬁlled with CO2. In addition to the behavioral fear response, in this
study, mice displayed a response that was comparable to the one
in humans on the physiological level. However, the predictive
validity of the rodent CO2 model is still to be determined. In
contrast to the widespread use of CO2 in human panic studies,
rodent studies in the framework of panic are still scarce. To
evaluate the predictive validity of the rodent model, future studies
could assess the effects of medication that is clinically effective in
humans. For instance, selective serotonin reuptake inhibitors are
often used in the treatment of PD43 and blunt the response to a
CO2 inhalation in humans.
8,44–46 It was also shown that the
decrease in the response to a CO2 challenge early in treatment
(after 1 week) precedes and predicts the later clinical response.45
Selective serotonin reuptake inhibitors are generally considered
as the ﬁrst-line pharmacological treatment option for PD;43
however, it was recently reported in a systematic review that
benzodiazepines appear to be superior regarding efﬁcacy and
side effects.47 Notably, some benzodiazepines (particularly clona-
zepam and alprazolam) also exert panicolytic effects on a CO2
inhalation.48–50
Thus, after pharmacological manipulation, it is expected that
animals respond less to CO2 than without treatment. The last
criterion, construct validity, is strongly supported by recent
studies. On the basis of a series of experiments in mice,
demonstrating an essential role of the acid-sensing ion channel
(ASIC) 1a in CO2-induced fear behavior,
27 genetic research in
humans has made progress. Recently, an association between
polymorphisms in the human homolog gene amiloride-sensitive
cation channel 2, encoding the pH-sensitive ion channel, and the
diagnosis of PD was reported.51 We investigated the effects of CO2
exposure as done in a seminal rodent study,27 showing a genetic
moderation of the same polymorphisms on the emotional
response in PD patients and on the physiological response in
healthy individuals.52 Previously, we proposed that an acutely
disturbed brain acid–base homeostasis represents the mechanism
underlying a (CO2-provoked) PA. This is supported by experiments
in rodents, demonstrating that CO2 exposure causes a drop in
brain pH,27,53 and evidence from intravenous bicarbonate infu-
sions points toward the same effect in humans.54 A shift out of the
normal physiological pH range can have life-threatening con-
sequences. ASIC1a as a pH detector that triggers adaptive
responses might therefore represent a key link between pH
changes and panic behavior. In addition to ASIC1a, accumulating
evidence involves orexin as another candidate involved in panic
states (for review see Johnson et al.55). Orexin is produced in CO2/
pH-sensitive hypothalamic neurons that regulate sympathetic
responses and blood pressure and project to brain regions
implicated in behavioral defense. Rodent research showed that
disinhibiting the orexin system is associated with developing a
panic-prone state, whereas administration of orexin receptor
antagonists block the panic response to CO2 exposure and sodium
lactate infusion. Furthermore, in humans, increased levels of
cerebrospinal orexin were found in subjects with panic anxiety.55
On the basis of these studies, the etiological processes between
the disorder in humans and the animal model appear to converge
toward high construct validity. Taken together, judging the three
validity criteria shows that the rodent CO2 model reﬂects the
aspects of PD well.
A cross-species model as used in the present study can strongly
facilitate the current understanding of the neural basis of a
disorder. Combining various dimensions such as behavior and
neurobiological measures might contribute to a more effective
and etiology-based diagnosis in line with the research domain
criteria framework, and eventually to new treatment options. At
least in panic research, it appears that the reactivity to CO2 in mice
can serve as a model for humans, and the reactivity in healthy
individuals as a model for PD patients. Thus, new potential
treatment strategies can be tested in mice and healthy individuals
before eventually being offered to patients.
A few considerations and future directions should be kept in
mind when interpreting the present data. First, PAs in PD occur
unexpectedly, which makes it challenging to study them in real
life. Therefore, we made use of a CO2 inhalation in the laboratory.
However, this does not reﬂect the unexpected nature of real-life
PAs. Future studies might beneﬁt from ambulatory assessments of
self-reports and physiological monitoring that have become more
feasible with the development of advanced systems.56 Thereby,
natural data and different states over the course of a day could be
captured. Although newer devices represent a promising
approach in this respect, the infrequency of real-life PAs might
lead to long assessment periods and healthy individuals could not
be studied anymore, as they do not experience naturally occurring
PAs. When studying experimental PAs using CO2 inhalations, it
might be interesting to examine potential subtypes as done in
previous studies in nonclinical participants.57,58 For instance,
assessing whether speciﬁc symptoms are present predominantly
at a particular concentration in patients might provide more in-
depth insights. Second, in humans, particularly one or two vital
capacity breaths of 35% CO2 are validated as the experimental
model for PAs (PD patients and healthy individuals, respectively),
which is not readily feasible to apply in mice. Apart from studying
the behavioral response, we (and others27) make use of a
prolonged exposure to a lower percentage in mice. Although this
percentage is not identical to the one in humans, the robust
behavioral fear response and the physiological response being
quantitatively similar to the one in humans suggests that the
model represents a panic model. Future studies are needed to
validate this model, also pharmacologically. Third, we did not
measure blood pressure in mice, as commonly used methods such
as a tail cuff do not allow assessment of freely moving animals.
Telemetry might be an alternative, but requires prior surgery.
Further, we did not obtain respiratory parameters in patients, as
ﬁxing the mask to the head was found unacceptable in a previous
pilot study in our laboratory. Smaller, less disturbing devices might
be an useful approach in future studies to be able to compare the
CO2-induced respiratory effects between samples.
To conclude, the present project uses the same experimental
stimulus as well as outcome measurements and quantitatively
compares the data between mice, healthy individuals and patients
to study a psychopathological phenomenon, demonstrating
corresponding effects across species. This model strongly
increases the efﬁcacy to translate knowledge generated in the
laboratory to human research and has a large potential to drive
forward, elucidating the molecular mechanisms involved in
the pathophysiology of PD and to extend basic discoveries into
the daily health practice. In the long run, this might be a step on
the road to a novel classiﬁcation of the diagnostic criteria for PD
incorporating the etiological basis, and to an improved and more
personalized treatment.
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